Meta-analysis of the results of intravenous gamma globulin treatment of coronary artery lesions in Kawasaki disease

Modern Rheumatology

Volumn 14, Issue 5, 2004, Pages 361-366

  Mori, Masaaki ^a   Miyamae, Takako ^a   Imagawa, Tomoyuki ^a   Katakura, Shigeki ^a   Kimura, Kazuhiro ^a   Yokota, Shumpei ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Coronary artery lesions (CALs); Gamma globulin; Kawasaki disease (KD); Meta analysis; Mucocutaneous lymph node syndrome

Indexed keywords

IMMUNOGLOBULIN;

ARTICLE; CHILD; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; META ANALYSIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; OUTCOMES RESEARCH; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 8444228161     PISSN: 14397595     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10165-004-0324-3     Document Type: Article

References (31)

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children: Clinical observation of 50 cases. Jpn J Allergy 1967;16:178-222.
2. Cassidy JT, Petty RE. Kawasaki disease. In: Cassidy JT, Petty RE, eds. Textbook of pediatric rheumatology. 4th edn. Philadelphia: Saunders; 2001. p. 580-94.
3. Suzuki A, Kamiya T, Kuwahara N, Ono Y, Kohata T, Takahashi O, et al. Coronary arterial lesions of Kawasaki disease: Cardiac catheterization findings of 1100 cases. Pediatr Cardiol 1986;7:3-9.
4. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. High-dose intravenous gamma-globulin for Kawasaki disease. Lancet 1984;2:1055-8.
5. Leung DY, Costran RS, Kurt-Jones E, Burns JC, Newburger JW, Pober JS. Endothelial cell activation and interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 1986;2:1298-302.
6. Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin-2 receptor, and interferon-γ in Kawasaki disease involved coronary lesions. Clin Immunol Immunopathol 1990;56:29-36.
7. Niwa Y, Shomiya K. Enhanced neutrophilic functions in mucocutaneous lymph node syndrome, with special reference to the possible role of increased oxygen intermediate generation in the pathogenesis of coronary thromboarteritis. J Pediatr 1984;104:56-60.
8. Terai M, Kohno Y, Namba M, Umemiya T, Niwa K, Nakajima H, et al. Class II major histocompatibility antigen expression on coronary arterial endothelium in a patient with Kawasaki disease. Hum Pathol 1990;21:231-4.
9. Sato N, Sugimura T, Akagi T, Yamakawa R, Hashino K, Eto G, et al. Selective high-dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatr Int 1999;41:1-7.
10. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-9.
11. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888-93.
12. Arjunan K, Daniels SR, Meyer RA . Coronary artery caliber in normal children and patients with Kawasaki disease but without aneurysms: An echocardiographic and angiographic study. J Am Coll Cardiol 1986;8:1119-24.
13. Agresti A. An introduction to categorical data analysis. Tokyo: Wiley; 1996.
14. Barron KS, Murphy DJ, Silverman ED, Ruttenberg HD, Wright GB, Franklin W, et al. Treatment of Kawasaki syndrome: A comparison of two dosage regimens of intravenously administered immune globulin. J Pediatr 1990;117:628-44.
15. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. Intravenous γ-globulin for Kawasaki disease. Acta Paediatr Jpn 1991;33:799-804.
16. Harada K. Intravenous γ-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 1991;33:805-10.
17. Hwang B, Lin CY, Hsieh KS, Tsuei DH, Meng CCL. High-dose intravenous gamma-globulin therapy in Kawasaki disease. Acta Paediatr Sin 1989;30:15-22.
18. Klassen TP, Rowe PC, Gafni A. Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome. J Pediatr 1993;122:538-42.
19. Matsushima M, Nagashima M, Matsuoka H, Ogawa A, Okumura N, Itoh S, et al. A controlled study of gamma globulin treatment for Kawasaki disease. J Jpn Pediatr Soc 1986;90:80-7 (in Japanese).
20. Morikawa Y, Ohashi Y, Harada K, Asai T, Okawa S, Nagashima M, et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatr Jpn 1994;36:347-54.
21. Nagashima M, Matsushima M, Matsuoka H, Ogawa A, Okumura N. High-dose gamma globulin therapy for Kawasaki disease. J Pediatr 1987;110:710-2.
22. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341-7.
23. Ogawa M, Ogino H, Harima Y, Kono S, Ohkuni H, Nishida M, et al. High-dose gamma globulin therapy for Kawasaki disease. J Jpn Pediatr Soc 1987;91:3763-71 (in Japanese).
24. Ogino H, Ogawa M, Harima Y, Kono S, Ohkuni H, Nishida M, et al. Clinical evaluation of gamma globulin preparations for the treatment of Kawasaki disease: Trial of 200 mg/kg/day for 3 days. J Jpn Pediatr Soc 1987;91:2849-56 (in Japanese).
25. Okuni M, Harada K, Yamaguchi H, Yanagawa H, Sonobe T, Kawasaki T. Intravenous gamma globulin therapy in Kawasaki disease: Trial of low dose gamma globulin. In: Shulman ST, ed. Kawasaki disease. New York: Liss; 1987. p. 433-9.
26. Onouchi Z, Isogai Y, Yanagisawa M, Yamauchi T, Matsuda H, Morita T, et al. Multicenter randomized controlled study of intravenous immunoglobulin in Kawasaki disease (in Japanese). J Jpn Pediatr Soc 1988;92:2367-76.
27. Onouchi Z, Yanagisawa M, Shiraishi H, Hirayama T, Katsube Y, Kiyosawa N, et al. Multicenter randomized controlled study of intravenous immunoglobulin G (C-425) for Kawasaki disease. 1. Study for optimal dosage and usefulness of C-425. J Jpn Pediatr Soc 1992;96:2669-79 (in Japanese).
28. Tomita Y, Iijima M, Fukaya T, Baba K, Yamakawa M, Hamahata K, et al. Clinical trial of a single intravenous infusion of gamma globulin and its flexible application as compared with five infusions in the treatment of acute Kawasaki disease. J Jpn Pediatr Soc 1995;99:1953-9 (in Japanese).
29. Yabiku M, Kojima S, Ogawa M, Ogino H, Harima Y, Kono S, et al. High-dose gamma globulin therapy for Kawasaki disease. J Jpn Pediatr Soc 1986;93:2713-20 (in Japanese).
30. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: A meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995;96:1057-61.
31. Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children (Cochrane review). In: The Cochrane Library, Issue 4. Chichester: Wiley; 2003.